WARN : Please note that some of the values may not be in base currency

Fundamental Analysis of Novo Nordisk A/S - Growth / Value Index


NVO - Valuation Highlights

Valuation Analysis

   Tsr Value Index - Excellent Score of 81.25
   Undervalued - Price to Intrinsic Value of 0.0217
   Price to Earning Ratio is 6.68 and EV to EBITDA is 4.87 suggesting company is undervalued.
   Tremendous increasing in Book Value last 3 year
   Price to Book Ratio of 6.36 suggesting that it is very expensive
Valuation Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Price to Earning 6.63 7.08 -34.38 %
Price to Book 6.31 5.56 -22.51 % 5.96
Price to Sales 2.42 2.55 -24.65 %
Enterprise Value to EBITDA Multiple 4.83 5.32 -32.90 %


NVO - Profitability Highlights

Profitability Analysis

   Tsr Profitability Index - Excellent Score of 82.50
   Piotroski F Score - Excellent Value of 8.0
   Earning Yield of 14.98 %
   Tremendous increasing trend in Net Profit for last 3 year
   Excellent Net Margin for last 3 years
   Over the last 3 years, the company has achieved Incredible Return on Equity
   Over the last 3 years, the company has achieved Incredible Return on Assets
   Excellent QoQ /QoQ FY EPS growth
   Strong Return On Capital Employed of 65.46
   Company Earning excess return
   During the past twelve months, the company has given a strong Return On Equity of 95.22%
   During the past twelve months, the company has given a strong Return On Asset of 30.91%
   During the past twelve months, the company has given a strong Net Margin of 36.55%
   All key Trailing Twelve Months Margin growing by 15 %
   EBITDA is continuously increasing for last 3 Years
   Steady Growth in EPS for last four quarters
Profitability Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Return On Equity 95.22 78.53 18.08 % 25.69
Return On Asset 30.91 26.61 15.62 % 8.50
Net Profit Margin 36.55 36.03 14.82 % 38.88
Operating Profit Margin 45.03 40.00 -5.39 % 49.60
EBITDA Margin 50.49 48.63 12.04 % 54.06


Highlights
Market Cap587548 M
Enterprise Value595610 M
Price/Book TTM6.31
Outstanding Share4454.84 M
Float/ Outstanding Share71.65%
Dividend Yield1.03 %
Share Holding
Guru Numbers
Price/Graham No1.28
Peter Lynch Ratio7.91
Piotroski F Score8.00
Altman Z Score3.87
Sloan Ratio-0.072
Peter Lynch Fair Value337.39


NVO - Growth Highlights

Growth Analysis

   Tremendous increasing trend in total sale last 3 year
   Steady increase in Total Assets for last 3 Years
Growth Key Fields
Field TTM YoY Growth QoQ Growth
Revenue 244243 M 31.26 % 0.780 %
Gross Profit 206744 M 32.32 % 0.745 %
EBITDA 123307 M 47.05 % 23.91 %
Net Profit 89276.00 M 50.71 % 15.68 %
EPS 19.91 52.38 % NA


NVO - Stability Highlights

Stability Analysis

   Tsr Stability Index - Good Score of 76.56
   Altman Z Score of 3.89 suggests good Stability
Stability Key Ratios
Ratio Latest FY Yoy Change MRQ
Debt to Equity Ratio 0.211 -20.90 % 0.272
Cash Ratio 0.178 -8.59 %
Quick Ratio 0.636 -8.27 % 0.500
Shareholders Equity 33.88 -2.08 %
Debt to EBITDA 0.199 -31.35 %


Historical Valuation Ratios of Novo Nordisk A/S

Historical Valuation Ratios
Loading ...

Historical Profitability Ratios of Novo Nordisk A/S

Historical Profitability Ratios
Loading ...

Historical Efficiency Ratios of Novo Nordisk A/S

Historical Efficiency Ratios
Loading ...

Historical Solvency Ratios of Novo Nordisk A/S

Historical Solvency Ratios
Loading ...


Note : All Data Generated at the End of Trading Hours (EOD Data)